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Abstract 
NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine 
potency and safety testing methods and to identify opportunities to advance new and improved methods that can further reduce, 
refine, and replace animal use. Six topics were addressed in detail by speakers and workshop participants and are reported in a 
series of six reports. This workshop report, the last in the series, addresses methods and strategies for veterinary vaccine post-
licensing safety testing that can reduce, refine, and replace animal use (the 3Rs). It also provides recommendations for priority 
research and other activities necessary to advance the development and/or implementation of 3Rs methods for veterinary vaccine 
post-licensing safety testing. Workshop participants gave priority for future efforts to vaccines that (1) use large numbers of 
animals per test, (2) produce large numbers of serials annually, (3) use additional animals for safety testing. They also prioritized 
poultry vaccines for which in vivo extraneous agent testing is still performed, adjuvanted vaccines that cause a site reaction, and 
vaccines that are well characterized. Vaccines identified as the highest priorities were those for avian diseases, rabies, 
Clostridium spp., and subunit protein and DNA vaccines, in addition to modified live viral products that do not contain 
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excipients. Workshop participants recommended priority research, development, and validation activities to address critical 
knowledge and data gaps, including opportunities to apply new science and technology. Recommendations included further 
assessment of the need for a general safety test; expanded application of primary cell culture and polymerase chain reaction 
(PCR) techniques to replace in vivo chicken tests for extraneous agents; development of in-process safety testing to verify 
detoxification of selected vaccines; and further investigation of cell-based assays to measure residual toxicity. Implementation of 
the workshop recommendations is expected to advance alternative methods for veterinary vaccine post-licensing safety testing 
that will benefit animal welfare and reduce or replace animal use while ensuring continued protection of human and animal 
health. 
 
© 2011 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of the National Toxicology Program 
Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) 
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1. Introduction 
Veterinary vaccines contribute to improved human and animal health and welfare by preventing infection and 
controlling infectious agents that can cause disease and death. However, the testing necessary to ensure vaccine 
effectiveness and safety can involve large numbers of animals and significant pain and distress. In the United States, 
the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the National 
Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) 
promote the scientific validation and regulatory acceptance of test methods that accurately assess the safety of 
chemicals and products while reducing, refining (less or no pain and distress), and replacing animal use. 
Accordingly, NICEATM and ICCVAM recently identified vaccine potency and safety testing as one of their four 
highest priorities [1].  
ICCVAM is an interagency committee of Federal agencies that is charged by law with evaluating new, revised, 
and alternative test methods with regulatory applicability. ICCVAM members represent 15 U.S. Federal regulatory 
and research agencies that require, use, generate, or disseminate safety testing data. These include the U.S. 
Department of Agriculture (USDA), which regulates veterinary vaccines, and the U.S. Food and Drug 
Administration (FDA), which regulates human vaccines. ICCVAM is a permanent interagency committee of the 
National Institute of Environmental Health Sciences (NIEHS) under NICEATM. NICEATM administers ICCVAM, 
provides scientific and operational support for ICCVAM-related activities, and conducts international validation 
studies on promising new safety testing methods. NICEATM and ICCVAM serve a critical public health role in 
translating research advances from the bench into standardized safety testing methods that can be used in regulatory 
practice to prevent disease and injury. 
To promote and advance the development and use of scientifically valid alternative methods for human and 
veterinary vaccine testing, NICEATM and ICCVAM organized the International Workshop on Alternative Methods 
to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing: State of the Science and 
Future Directions. The workshop was held at the National Institutes of Health in Bethesda, Maryland, on September 
14–16, 2010. It was organized in conjunction with the European Centre for the Validation of Alternative Methods 
(ECVAM), the Japanese Center for the Validation of Alternative Methods (JaCVAM), and Health Canada. 
The workshop addressed the state of the science of human and veterinary vaccine potency and safety testing. 
Participants developed recommendations for future progress in three major areas: (1) in vitro replacement methods 
for potency testing; (2) reduction and refinement methods for potency testing; and (3) reduction, refinement, and 
replacement methods for vaccine safety testing [2]. Each report incorporates the contributions of invited experts and 
the general public during the various plenary presentations and dedicated breakout group sessions [3, 4, 5, 6, 7, 8]. 
This report addresses methods and strategies for the reduction, refinement, and replacement of animal use for post-
licensing safety testing of veterinary vaccines. 
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2. Goals and organization of the workshop 
The goals of the international workshop were to (1) identify and promote the implementation of currently 
available and accepted alternative methods that can reduce, refine, and replace the use of animals in human and 
veterinary vaccine potency and safety testing; (2) review the state of the science of alternative methods and identify 
knowledge and data gaps that need to be addressed; and (3) identify and prioritize research, development, and 
validation efforts needed to address these gaps in order to advance alternative methods that will also also ensure 
continued protection of human and animal health. 
The workshop was organized with four plenary sessions and three breakout group sessions. In the breakout 
sessions, workshop participants:  
• Identified criteria to prioritize vaccine potency and safety tests for future alternative test method development, 
and identified high priorities using these criteria 
• Reviewed the current state of the science of alternative methods and discussed ways to promote the 
implementation of available methods 
• Identified knowledge and data gaps that need to be addressed 
• Identified and prioritized research, development, and validation efforts needed to address these gaps in order to 
advance alternative methods while ensuring continued protection of human and animal health 
The workshop opened with a plenary session in which expert scientists and regulatory authorities from the United 
States, Europe, Japan, and Canada outlined the importance of vaccines to human and animal health [9, 10] and 
described national and international regulatory testing requirements for human and veterinary vaccines [2, 11, 12, 
13, 14, 15, 15]. Authorities emphasized that, following the approval of a vaccine, testing is required to ensure that 
each subsequent production lot is pure, safe, and potent enough to generate a protective immune response in people 
or animals [11, 12]. 
The second plenary session addressed methods that have been accepted and methods that are in development that 
do not require the use of animals for assessing the potency of vaccines [17, 18, 19, 20]. This was followed by 
breakout sessions to discuss the state of the science and recommendations for future progress for in vitro potency 
tests for human and veterinary vaccines. Workshop recommendations to advance the use and development of 
alternative methods that can replace animals for the potency testing of human [3] and veterinary vaccines [4] are 
available elsewhere in these proceedings.  
The third plenary session addressed (1) potency testing methods that refine procedures to avoid or lessen pain and 
distress by incorporating earlier humane endpoints or by using antibody quantification tests instead of challenge 
tests and (2) methods and approaches that reduce the number of animals required for each test [21, 22, 23, 24, 25, 
26, 27]. Breakout groups then discussed the state of the science and developed recommendations for future progress. 
Workshop recommendations to advance the use and development of alternative methods that can reduce and refine 
animal use for potency testing of human vaccines [5] and veterinary vaccines [6] are available elsewhere in these 
proceedings. 
The final plenary session addressed methods and approaches for reducing, refining, and replacing animal use to 
assess the safety of serial production lots of human and veterinary vaccines [11, 28, 29, 30]. Breakout groups then 
discussed the state of the science and developed recommendations for advancing alternative methods for vaccine 
safety testing. Workshop recommendations to advance the use and development of alternative methods for safety 
testing of human vaccines [7] are available elsewhere in these proceedings. Recommendations for veterinary 
vaccines are provided in this paper. 
3. Requirements for veterinary vaccine post-licensing safety testing  
For both human and veterinary vaccines, strict regulatory guidelines ensure that vaccines released for sale are 
pure, safe, potent, and effective [31]. In the United States alone, approximately 18,000 serials (batches) are released 
annually for approximately 2000 different products that protect animals from 213 different animal diseases [12].  
Veterinary vaccines are necessary to (1) ensure a safe and efficient global food supply, (2) control diseases of 
companion animals and domestic animals, and (3) reduce the transmission of zoonotic and food borne infections to 
people [9]. In addition, safe and effective vaccines reduce the need for low-level antibiotics to treat sick animals and 
control some diseases in food animals [9].  
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Due to the number of animals used annually for the release of veterinary vaccines, global regulatory agencies 
actively encourage the evaluation, development, and implementation of novel approaches that reduce, refine, and 
replace (3Rs) the use of animals in vaccine potency and safety product release testing [12, 14, 22].  
Post-licensing safety testing of each vaccine production batch is intended to address a number of potential safety 
issues, confirming that (1) there has been complete inactivation of virulent organisms in products containing killed 
viruses and bacteria; (2) the product does not contain toxic substances, such as incompletely neutralized inactivating 
agents; (3) unknown toxic compounds were not inadvertently introduced during the vaccine manufacturing process; 
and (4) unknown virulent extraneous agents or other contaminants were not inadvertently introduced during the 
manufacturing process. Safety implies the absence of residual virulence (for live attenuated vaccines), freedom from 
extraneous infectious agents, and the absence of toxicity. 
4. Veterinary vaccine post-licensing safety testing: priority vaccines for future research, development, and 
validation activities  
Workshop participants identified criteria that should be considered in prioritizing veterinary vaccine post-
licensing safety tests for further development and validation of 3Rs methods. Criteria included safety tests for 
vaccines that:  
• Use large number of animals per test 
• Cause animal pain and distress  
• Have a large number of serials produced annually  
• Use additional animals for safety testing (i.e., a safety assessment cannot be performed using animals from the in 
vivo potency test) 
• Are used for poultry and for which in vivo extraneous agent testing is still performed 
• Contain adjuvants that cause an injection site-related reaction 
• Have the protective antigen identified and adequately characterized  
Based on these criteria, the highest priority vaccines for further development of alternative methods for safety 
testing include:  
• Avian vaccines  
• Rabies vaccines  
• Clostridium spp. vaccines 
• Subunit protein and DNA vaccines  
• Modified live viral products that do not contain excipients  
Avian, rabies, and Clostridium spp. vaccines were identified as the highest priorities because their required safety 
tests use large numbers of animals, and the vaccines are produced in large numbers each year. Another reason for 
prioritizing avian vaccines is a need to replace in vivo extraneous agent testing with in vitro (i.e., polymerase chain 
reaction [PCR]) methods. Subunit protein and DNA vaccines, as well as modified live products without excipients, 
were also prioritized because they have a lower likelihood of adverse reactions. Workshop participants emphasized 
that cell-based alternatives may not be appropriate for many inactivated vaccines due to the presence of adjuvants or 
other excipients that are nontoxic in vivo but are toxic to cells in culture. 
5. Alternative methods for veterinary vaccine post-licensing safety testing: state of the science; knowledge 
gaps; and priority research, development, and validation activities  
5.1. State of the science 
5.1.1. General safety test 
5.1.1.1. United States 
In the United States, all veterinary vaccine batches must meet the safety criteria defined in Title 9 of the U.S. 
Code of Federal Regulations [32] prior to release. If potency testing procedures require the use of target (host) 
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animals, those animals are also observed for adverse reactions. Separate safety testing is generally not required. 
However, if potency testing is conducted in laboratory animal models or in vitro, separate target (host) or laboratory 
animal batch release safety tests are typically required. Safety testing serves multiple purposes; and strategies for 
reducing, refining, and replacing the use of animals must address all of them on a case-by-case basis. As specified in 
U.S. codified safety tests, a minimum number of target animals (e.g., dog, cat, calf, horse, pig, chicken, salmon) are 
tested at 1x, 2x, or 10x doses. In the mouse safety test [33], 0.5 mL of each dose is administered (intraperitoneal or 
subcutaneous) to groups of eight animals that each are then observed for seven days. By comparison, in the guinea 
pig safety test [34], 2.0 mL of each dose is administered (intramuscular or subcutaneous) to groups of two guinea 
pigs that each are then observed for seven days. 
5.1.1.2. Europe 
In Europe, the general safety test in laboratory animals, typically known as the abnormal toxicity test (ATT), has 
been eliminated for veterinary vaccines because of the test’s inability to detect unsafe batches and thus its lack of 
relevance as a criterion for vaccine release testing. Therefore, only target animals are used for safety testing now. 
The European target animal safety test (TAST) typically uses two animals for mammalian vaccines, 10 for chicken 
vaccines, and at least 10 for fish vaccines [14]. Target animals are injected with either a 2x dose of an inactivated 
vaccine or a 10x dose of a live vaccine. Test animals are then observed for any abnormal or systemic reactions to the 
vaccine over a given period of time (typically 14–28 days).  
European Pharmacopoeia Monograph 062 – Vaccines for Veterinary Use (Ph. Eur. 062) [35] currently allows for 
elimination of the target animal batch release safety test on a case-by-case basis. Manufacturers request a “waiver 
by the competent authority in the interests of animal welfare when a sufficient number of consecutive 
batches have been produced and found to comply with the test, thus demonstrating consistency of the 
manufacturing process. Significant changes to the manufacturing process may require resumption of 
routine testing to re-establish consistency". A report from an independent third-party expert addresses inherent 
variability, intrinsic safety margin, and validation data in support of quality and safety. If the manufacturing process 
is significantly changed, it may be necessary to reinstate the target animal batch release safety test to reestablish 
consistency. To date, target release safety tests have been waived for some products based on consistency and 
alternative quality controls [28].  
The “consistency approach” implies that the routine release of vaccines is based upon the principle that the 
quality of vaccine is a consequence of a quality system of consistent production of batches with similar 
characteristics to those batches that have been shown to be safe and effective in the target species [36, 37, 38]. This 
concept includes standardized manufacturing procedures, the use of master seed and master cell banks, in-process 
controls, minimum and maximum limits set for antigen content in vaccines, and a system for pharmacovigilance.  
In a preliminary analysis of target animals used for testing of batches released in the United Kingdom from 2007 
to 2009, roughly 50% were chickens, 25% fish, and the remaining 25% divided between cattle, pigs, horses, and 
sheep [14]. Based on these data, the greatest decrease in animal use (i.e., removing or waiving of safety tests) may 
be achieved with fish and chickens, which accounted for 75% of the animals used for target safety testing 
procedures during this period. Because these tests can currently be waived in the Europe with the demonstration of 
consistency after safe production of 10 consecutive batches, no further research or validation is necessary, except the 
initiative of the vaccine manufacturer to apply for a waiver with their respective data. 
5.1.1.3. Japan 
In Japan, batch safety testing is performed in target species for all vaccines except inactivated vaccines used for 
large animals. Inactivated vaccines for other species are tested with a 1x dose injection, and live vaccines for all 
species are tested with an overdose [39]. 
5.1.2. Extraneous agent testing 
More appropriate and specific vaccine safety testing procedures are now available to address the presence of 
extraneous agents. For extraneous agent testing in poultry vaccines, the European Pharmacopoeia (Ph. Eur.) requires 
that products be monitored for many potential contaminants. The specific tests are described in individual 
monographs and Ph. Eur. 2.6.25 [40] (Avian live virus vaccines: tests for extraneous agents in batches of finished 
product). The safety methods currently in use include both animal and non-animal tests performed on each batch 
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(serial) of vaccine. The tests utilize eggs, cell culture, and SPF chicks to cover the range of potential contaminants. 
Briefly, the in vivo test in chicks involves the inoculation of 10 2-week old SPF chicks with multiple injections of 
the vaccine product by both intramuscular and eye drop injection. Multiple injections significantly improve the 
sensitivity of the test. Serum is collected from each chick prior to inoculation and after the testing period. Animals 
are observed for mild signs of infectious disease, and the serum samples are tested for antibodies against a list of 
infectious agents. The vaccination must not induce the production of antibody against specific viruses. The in vivo 
test in chicks encompasses 16 infectious diseases [41].  
Recent development of more technologically advanced molecular methods has increased their use in the quality 
control of veterinary vaccine products. For example, the utilization of a PCR technique for extraneous agent testing 
of both live and inactivated poultry vaccines has been identified as a valuable alternative testing method to replace 
the use of animals in quality control testing [41, 42, 43]. Results so far indicate that the sensitivity of the PCR 
procedure is at least equal to or, in most cases, higher than that of conventional in vivo testing. In addition to the 
higher sensitivity, PCR tests also eliminate the use of animals and have faster turnaround times [44].  
PCR tests are now available for 15 different extraneous agents tested in avian vaccines, including avian 
adenoviruses, avian infectious bronchitis virus, chicken anemia virus, infectious bursal disease virus, and Newcastle 
disease virus [44]. Following the acceptance and implementation of these methods, the number of chickens used in 
the United Kingdom between 2007 and 2009 was reduced by approximately 50% (Woodland personal 
communication). A complete list of available alternative assays including PCR, primary cell culture methods, and 
egg methods is provided in the ECVAM workshop report “Three Rs Approaches in the Production and Quality 
Control of Avian Vaccines” [41]. 
For nonavian vaccines, the extraneous agent test can be combined with the target animal safety test. Examples 
include selected bovine vaccines (corona, rotavirus) and porcine vaccines (parvo) that utilize serological testing of 
test animals used in the general safety tests. 
5.1.3. Inactivation and residual toxicity tests 
A residual live virus test is required to confirm that inactivated human and veterinary rabies vaccines are in fact 
inactivated [45]. For veterinary rabies vaccines, the USDA requires that 20 mice be injected intracerebrally with 
0.25 mL of vaccine product and observed daily for 21 days. If any mice die between Day 4 and Day 21, brain 
material is recovered and injected into five additional mice [46]. The World Organisation for Animal Health (OIE) 
guidelines includes the use of an in vitro cell culture test, as well as the in vivo mouse test [47]. The cell-based 
method can accommodate a much higher number of equivalent doses than can be injected into mice or rabbits. 
Results to date indicate that the fluorescent antibody technique in cell culture is at least as sensitive as the mouse 
test; however, the test should be performed prior to the addition of adjuvants and preservatives [48]. The report and 
recommendation of ECVAM Workshop 48 stated that “the test for residual live virus should be conducted on the 
bulk material by using cell cultures, and the test in mice and rabbits should be deleted as a finished product test” 
[45]. However, to date, Ph. Eur. Monograph 0451 [49] still includes the in vivo test in mice for the finished product. 
Workshop participants emphasized that any proposed reduction, refinement, and replacement alternative method 
must adequately address the safety objective for the original test. Extensive studies may be necessary to replace 
currently implemented in vivo safety methods. However, implementation and use of stringent in-process controls 
during the vaccine manufacturing process may help reduce animal use. Vaccine manufacturers who can demonstrate 
highly refined, consistent manufacturing processes and appropriate biocontainment and disinfection processes may 
also be able to justify exemptions on a product-by-product basis.  
Some workshop participants expressed significant concerns regarding this strategy. There may be insufficient 
data to support a relationship between stringent manufacturing processes and safety risks at this time. In addition, 
some regulatory agencies may not have adequate resources to develop and apply consistent approaches for 
conducting risk assessment on a product-by-product basis. Furthermore, post-marketing adverse event reporting by 
veterinary vaccine manufacturers is not currently a global requirement. Therefore, safety problems with individual 
batches of vaccine products may go undetected. For this reason, many veterinary vaccine manufacturers still hesitate 
to release batches of vaccine product that have not been tested for safety in animals. Even with the implementation 
of revised safety testing regulations, manufacturers may continue to conduct animal testing for liability and ethical 
concerns. In addition, U.S. manufacturers are typically allowed a broader range of antigenic material with a clear 
minimum, but not a maximum, as defined in the outline of production. Consequently, it is anticipated that the upper 
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limit would be set both by cost considerations and by vaccine safety testing data, further outlining the perceived 
value of the general safety test in the United States. 
A simple alternative to reduce animal use in vaccine safety testing would be to combine it with potency testing. 
For example, if potency testing of a veterinary vaccine product requires the use of target animals, these animals may 
also be observed for adverse reactions/clinical signs. Additional safety testing would therefore not be required. 
Specific examples of vaccines for which this approach has been implemented include mink enteritis vaccine [50] 
Newcastle disease vaccine [51], bovine virus diarrhea vaccine [52], canine distemper virus [53], and canine 
parainfluenza vaccine [54] (Table 1). In addition, potency and safety testing procedures for avian influenza vaccine 
are performed simultaneously in chickens. Relative potency of this vaccine product is determined by 
hemagglutination inhibition titers in blood samples collected three weeks after vaccination [28]. The same test 
animals are also observed for safety effects during the 3-week observation period. However, if relative potency 
testing is conducted in laboratory animals or in vitro, separate host animal safety tests are still required. 
 
 
Table 1: Examples of veterinary vaccine post-licensing safety tests that incorporate reduction, refinement, 
and replacement alternative methods 
 
Vaccine Product/ 
Test Available 3Rs Method 
Traditional Safety 
Test 
Regulatory 
References 
Scientific 
References 
General      
Vaccines for 
veterinary use 
Submission of data to support waiver of 
target animal safety test as stated in the 
current Ph. Eur.: "For an established 
vaccine the routine application of the 
safety test may be waived by the 
competent authority in the interests of 
animal welfare when a sufficient number 
of consecutive batches have been 
produced and found to comply with the 
test, thus demonstrating consistency of 
the manufacturing process. Significant 
changes to the manufacturing process 
may require resumption of routine 
testing to re-establish consistency" a
Target animal 
safety 
Ph. Eur. Monograph 
62 [52]; Ph. Eur. 5.2.6 
[55]; Ph. Eur. 5.2.9 
[56] 
 
Weisser and 
Hechler 1997 [57]; 
Cussler and 
Poessnecker 2000 
[58]; AGAATI 
2002 [59] 
Viral Vaccines     
Mouse safety Intraperitoneal or subcutaneous 
inoculation of mice for live virus 
vaccines 
Intracerebral and 
intraperitoneal 
inoculation of mice 
for live virus 
vaccines 
9 CFR 113.33 [33]; 
CVB Notice No. 05-01 
[60] 
- 
Avian live virus 
vaccines 
Embryonated hen’s eggsb, cell cultureb, 
PCRb
Chicken extraneous 
agent testc
Ph. Eur. 2.6.25 [40] Bruckner et al. 2000 
[41]; Ottiger 2006 
[43]; Ottiger 2010 
[44] 
Canine distemper 
vaccine 
(CDV) 
Combining potency and safety tests 
eliminates need for separate target 
animal testing for general safety test 
Observation of 
vaccinated dogs 
used in potency test 
9 CFR 113.201 [53] - 
Mink enteritis 
vaccine;  
Mink enteritis virus 
Combining potency and safety tests 
eliminates need for separate target 
animal testing for general safety test 
Observation of 
vaccinated mink 
used in potency test 
9 CFR 113.204 [50] - 
Newcastle disease 
vaccine: 
chickens 
Combining potency and safety tests 
eliminates need for separate target 
animal testing for general safety test 
Observation of 
vaccinated chickens 
used in potency test  
9 CFR 113.205 [51] - 
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Vaccine Product/ 
Test Available 3Rs Method 
Traditional Safety 
Test 
Regulatory 
References 
Scientific 
References 
Bovine virus 
diarrhea vaccine; 
BVD virus 
Combining potency and safety tests 
eliminates need for separate target 
animal testing for general safety test 
Observation of 
vaccinated calves 
used in potency test  
9 CFR 113.215 [52] - 
Canine 
parainfluenza 
vaccine 
Combining potency and safety tests 
eliminates need for separate target 
animal testing for general safety test 
Observation of 
vaccinated dogs 
used in potency test 
(For live virus 
vaccines, a mouse 
safety test is also 
conducted unless 
the virus or agent in 
the vaccine is 
inherently lethal for 
mice.) 
9 CFR 113.316 [54] - 
aThe target animal safety test can be waived after demonstration of consistency, i.e., the product passes the target animal safety test in at least 
10 consecutive batches.  
bPublished in the European Pharmacopoeia  
cExtraneous agent test for live avian vaccines no longer uses animals in Europe 
 
5.2. Knowledge gaps and priority research, development, and validation activities 
A critical knowledge gap is a definitive understanding of the range of possible causes that result in a failed 
general vaccine safety test for each vaccine. Workshop participants recommended that the historical basis for 
instituting the general safety test be carefully reviewed in order to define the need for its continuation. Specifically, 
the basis for failed safety tests and/or the relative frequency of their occurrence must be determined. These data are 
not readily available because veterinary vaccine manufacturers generally do not provide regulatory agencies with 
detailed safety testing failure information. Workshop participants recommended that a collaborative study between 
vaccine manufacturers and global regulatory agencies be initiated to evaluate the value of and need for general 
safety testing.  
The global differences in standardization of the maximum allowable antigen content should be further discussed. 
For example, antigen maximum limits are clearly defined in the Europe but not in the United States. As stated 
earlier, veterinary vaccine manufacturers in the United States are typically allowed a broader range of antigenic 
material with a clear minimum, but not a maximum, as defined in the outline of production. If a maximum allowable 
antigen content limit was to be implemented in the United States, it might eliminate the need for 10x and 2x vaccine 
safety testing. However, this resolution may be at odds with a vaccine manufacturer’s desire to increase antigen 
content in selected veterinary vaccines in order to maintain the vaccines’ stability and increase shelf-life.  
Another knowledge gap identified at the workshop involved an understanding of the relationship between 
endotoxin content and/or mouse toxicity test results and field adverse reporting. Workshop participants 
recommended defining the correlation between endotoxin testing and the prelicensing serial data to set an upper 
limit on endotoxin content. Users would conduct additional toxicity testing only if that upper endotoxin limit is 
exceeded in specific batches of veterinary vaccines.  
A final concern discussed at the workshop was the ability, or inability, to correlate proposed alternative assays 
with currently implemented vaccine safety tests. Participants noted that extensive research, development, and 
validation studies would be required to ensure that substitute assays accomplish the same objectives as current in 
vivo vaccine safety testing procedures.  
The highest priority research, development, and validation activity identified by workshop participants was 
critical analysis of target species and laboratory safety data to more accurately determine the basis of why and how 
often vaccine safety tests fail. As stated earlier, the safety testing of each batch (serial) of vaccine product in target 
and/or laboratory animals remains a global requirement for vaccine release.  
A second priority is expanding the application of primary cell culture and PCR techniques to poultry vaccines. 
These techniques represent promising approaches to replace the in vivo chicken extraneous agent test [44].  
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Another priority is determining if the in vivo veterinary rabies inactivation test could be replaced with primary or 
other cell culture techniques. Such an approach is now included in EDQM guidelines for testing of virus inactivation 
for human rabies virus vaccines [61]. This approach has yet to be applied to veterinary rabies vaccines and was 
therefore identified as a key priority.  
Finally, workshop participants recommended the use of in-process safety testing to verify detoxification of 
selected vaccines (e.g., Clostridium spp.). They recommended that cell-based assays be considered to measure 
residual toxicity [62]. 
6. Application of human vaccine post-licensing safety testing to veterinary vaccines: reduction, refinement, 
and replacement alternative methods  
Progress has recently been achieved in the development and validation of alternatives that reduce, refine, and 
replace the use of animals in the safety testing of human vaccine products. These alternatives should be reviewed 
and applied as appropriate to veterinary vaccines (and vice versa). In general, human vaccines are better 
characterized than veterinary vaccines and contain fewer excipients and/or less complex adjuvants that could 
interfere with in vitro testing procedures. Therefore, modified live veterinary vaccines (instead of inactivated 
vaccines that contain complex adjuvants and excipients) are the favored candidates to consider for the application of 
human vaccine safety testing 3Rs methods. However, one possible approach for inactivated bacterial veterinary 
vaccines is to assess in vitro tests currently in development to detect residual toxicity in human tetanus vaccines. 
Several in vitro methods, including binding and enzymatic assays, have been described [62]. 
7. Achieving broader acceptance and use of currently available reduction, refinement, and replacement 
methods for veterinary vaccine post-licensing safety testing  
Workshop participants agreed that broader acceptance and use of 3Rs alternative methods for veterinary vaccine 
safety testing requires the successful harmonization of quality control and assurance procedures by both national and 
international regulatory agencies. An existing program that can assist in this effort is the International Cooperation 
on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). The VICH 
is a collaborative program primarily between regulatory authorities and animal health industries of the EU, Japan, 
and the United States. The VICH aims to harmonize technical requirements for the registration of veterinary 
medicinal products by establishing and implementing specific guidelines following extensive input and review from 
global regulatory agencies.  
The VICH was originally established under the auspices of the OIE. The OIE participates as an associate member 
by supporting and disseminating VICH recommendations and guidelines on a global stage (http://www.vichsec.org). 
As stated earlier, VICH guidelines are developed through collaborations with the international scientific community, 
thereby ensuring broader review and acceptance of the regulatory guidance principles and facilitating a more rapid 
and uniform implementation. Specific examples of VICH guidelines that have been adapted by the USDA’s Animal 
and Plant Health Inspection Service (APHIS) include VICH Guideline number GL 41: Target Animal Safety – 
Examination of Live Veterinary Vaccines in Target Animals for Absence of Reversion to Virulence [63] (2008) 
(adopted in the United States in 2008) and GL 44: Target Animal Safety for Veterinary Live and Inactivated 
Vaccines [64] (2009) (adopted in the United States in 2010).  
Workshop participants recommended that all VICH harmonization initiatives on product safety be 
comprehensively reviewed and that relevant data be provided to fill existing knowledge gaps. Specifically, a review 
and endorsement of the draft guidelines/criteria for requirements to request a waiver for target animal safety testing 
was considered a high priority (Harmonisation of Criteria to Waive Batch Safety Testing for Inactivated Vaccines 
for Veterinary Use). In addition, workshop participants encouraged the broad adoption of the VICH guidelines for 
pharmacovigilance (Guidelines 24, 29, 30, 35, and 42) [65]. 
Finally, there was extensive dialogue regarding application of the consistency approach to the removal of the 
target animal batch release safety test. During the workshop, participants raised concerns about how consistency can 
be adequately demonstrated and what specific data and performance are required for a safety test or any other test to 
be waived. In general, the participants agreed that, to facilitate its successful global implementation, a consistency 
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approach for waiving vaccine testing would require the application of stringent process controls throughout the 
manufacturing process with suitability assessed on a product-by-product basis. 
8. Other issues to be addressed to facilitate the reduction, refinement, and replacement of animals in 
veterinary vaccine post-licensing safety testing  
A key issue identified at the workshop was replacing the general batch release safety test performed in target 
and/or laboratory animals. There was consensus that further discussion will require (1) a review of product release 
historical data and (2) broader access to in-process data such as endotoxin testing results. In addition, these 
discussions will require the active participation of every major regulatory agency in order to achieve the successful 
elimination of the vaccine safety test at a global level. Workshop participants also proposed that regulatory agencies 
should remain flexible as better-defined veterinary products are developed. They suggested that it may not be 
necessary to proceed automatically to traditional animal-based safety tests for future vaccine products.  
Additionally, the participants requested that information describing successfully implemented testing methods be 
more openly accessible. Accordingly, a specific proposal was introduced requesting public internet access and free 
availability of the Ph. Eur. monographs.  
The key issues of insufficient research funding and adequate incentives for vaccine manufacturers need to be 
addressed in order to reduce animal use for veterinary vaccine safety testing. Funding support from government 
granting agencies, industry associations, and animal welfare advocacy groups could significantly accelerate this 
process. Also, increased academic research into the development of alternative safety testing procedures needs to be 
promoted and encouraged.  
Further incentives for industry stakeholders to develop, validate, and implement alternative vaccine safety testing 
methods need to be clearly conveyed and implemented by regulatory agencies. Workshop participants identified 
incentives that may be considered attractive to relevant vaccine manufacturers, including (1) an expedited regulatory 
review time, (2) waiver of the variation fee (if applicable), and (3) the opportunity to utilize intermittent in vivo/in 
vitro parallel data to expedite validation of new in vitro methods. 
9. Discussion 
This was the first international workshop in the United States to focus on the reduction, refinement, and 
replacement of animal use for potency and safety release testing of both human and veterinary vaccines. A key 
accomplishment of the workshop was bringing together experts from industry, academia, and government in the 
areas of potency and safety testing for both human and veterinary vaccines. Participants, particularly/especially 
vaccine manufacturers and regulatory authorities, agreed that the workshop facilitated information exchange not 
only between global regions but also between regulatory authorities in the same country. This interaction leads to 
potential acceleration in the development of alternative methods once priorities are firmly established.  
Workshop participants addressed the state of the science of 3Rs alternative methods for veterinary vaccine post-
licensing safety testing and provided recommendations for priority research and other activities necessary to 
advance the development and/or implementation of these alternative methods. 
At this time, all veterinary vaccine products still require a batch release safety test in target or laboratory animals 
prior to release. In the Europe the target animal test may be waived with the demonstration of manufacturing 
consistency and the successful safety testing and release of 10 consecutive batches. For regulatory authorities 
outside Europe to consider waiving either the laboratory or target animal safety test a broad international assessment 
of historical safety data (both in-process and release testing) would be necessary to determine the extent to which the 
alternative approaches can adequately identify unsafe batches (serials) of vaccine on a product-specific basis. This 
process will require extensive collaboration between interested stakeholders (e.g., vaccine manufacturers, regulatory 
agencies) and may lead to the standardization of safety test methods. Participants recognized that any 
implementation initiative should commence with nonadjuvanted, better-characterized vaccines. Furthermore, as 
reduction, refinement, and replacement alternative methods are validated and accepted, the methods should be 
published and made available in the public domain.  
Continued efforts should be made to assess general safety as part of the in vivo potency release test, which could 
significantly reduce the number of animals used for safety testing. A recommended first priority was to assess the 
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general safety test for fish vaccines. In addition, it may be necessary to supplement the in vivo safety test with in 
vitro methods of safety assessment. Methods such as serology, cell-based assays, and ELISAs, may help to develop 
sufficient information on residual virulence (for live attenuated vaccine), freedom from extraneous agents, and the 
absence of toxicity to support elimination of the general safety test. A key initiative of the workshop was to 
encourage the broader adaptation of PCR testing for extraneous agents in regions where in vivo techniques are still 
in use. To achieve this goal, opportunities for technical training must be provided. In some cases, the necessary 
equipment to conduct the testing must be made available.  
Workshop participants gave high priority to further investigation to determine if the in vivo veterinary rabies 
inactivation test may be replaced with cell culture techniques already in use for the testing of virus inactivation for 
human rabies virus. With an in vitro test already validated and in use, its application to veterinary vaccines could be 
rapidly explored to reduce animal use as well as to improve test sensitivity and improve review times for product 
release. 
A key recommendation of the workshop was that all VICH harmonization initiatives on product safety should be 
comprehensively reviewed. In particular, a review and endorsement of the draft guidelines/criteria for requirements 
to request a waiver for target animal safety testing was considered a high priority. There was broad support for 
adoption of the VICH guidelines for pharmacovigilance to ensure that there are universal criteria for the reporting of 
adverse events to ensure a safe and effective veterinary vaccine supply. Adoption of the VICH guidelines would in 
turn support changes in the safety assessment process by enhancing the ability to detect any failures in an alternative 
process (http://www.vichsec.org). Such actions would support the larger goal of international harmonization of 
safety testing procedures. As part of these efforts, workshop participants recommended broader access to 
information describing vaccine safety testing methods that have already been successfully implemented. A specific 
workshop recommendation was that there should be public internet access and free availability of the Ph. Eur. 
monographs and other regulatory guidelines.  
The key issues of insufficient research funding and adequate incentives for vaccine manufacturers need to be 
addressed in order to reduce animal use for veterinary vaccine safety testing. Funding support by government 
granting agencies, industry associations, and animal welfare advocacy groups could significantly accelerate this 
process. Furthermore, increased academic research into the development of alternative safety testing procedures 
needs to be actively encouraged.  
Further incentives for industry stakeholders to develop, validate, and implement alternative methods need to be 
clearly conveyed and implemented by regulatory agencies. Workshop participants identified incentives that may be 
considered attractive to relevant vaccine manufacturers, including (1) an expedited regulatory review time, 
(2) waiver of the variation fee (if applicable), and (3) the opportunity to utilize intermittent in vivo/in vitro parallel 
data to expedite validation of new in vitro methods.  
The process of reduction, refinement, and replacement of animal use for veterinary vaccine safety testing will 
require collaboration among manufacturers, regulators, and international organizations such as the VICH and the 
OIE. Incentives to streamline the regulatory process will assist in more rapid implementation. 
10. Conclusion 
This workshop session reviewed the current status of veterinary vaccine post-licensing safety testing and 
identified research, development, and validation activities necessary to further advance testing methods and 
strategies that would use fewer or no animals. The session identified opportunities for expanded use of in vitro 
safety tests such as PCR for extraneous agent testing, cell culture techniques to confirm virus inactivation, and cell-
based assays to assess residual toxicity. Expanded application and implementation of these available alternative 
methods are expected to further reduce animal use for safety testing. Workshop participants also acknowledged the 
opportunity for developing batteries of validated parameters to assess final product consistency as a potential 
substitute for in vivo safety testing. Finally, workshop participants recommended stronger collaboration among the 
global human and veterinary vaccine communities to expedite further reduction and replacement of animals for 
vaccine testing while ensuring the safety of people and animals. 
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